WEKO3
アイテム
{"_buckets": {"deposit": "0cf90518-611e-4ac3-9732-2d7f7b0d6e1a"}, "_deposit": {"created_by": 11, "id": "2917", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "2917"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00002917", "sets": ["37"]}, "author_link": [], "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "358", "bibliographicPageStart": "350", "bibliographicVolumeNumber": "13", "bibliographic_titles": [{"bibliographic_title": "Clinical Genitourinary Cancer", "bibliographic_titleLang": "en"}]}]}, "item_6_date_granted_70": {"attribute_name": "学位授与年月日", "attribute_value_mlt": [{"subitem_dategranted": "2015-09-09"}]}, "item_6_degree_grantor_68": {"attribute_name": "学位授与機関", "attribute_value_mlt": [{"subitem_degreegrantor": [{"subitem_degreegrantor_language": "ja", "subitem_degreegrantor_name": "滋賀医科大学"}], "subitem_degreegrantor_identifier": [{"subitem_degreegrantor_identifier_name": "14202", "subitem_degreegrantor_identifier_scheme": "kakenhi"}]}]}, "item_6_degree_name_67": {"attribute_name": "学位名", "attribute_value_mlt": [{"subitem_degreename": "博士(医学)", "subitem_degreename_language": "ja"}]}, "item_6_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background:\nSunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). Sunitinib pharmacokinetics shows a large interpatient variability. ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "Patients and methods:\nA retrospective, observational clinical study of 21 patients with RCC was performed. Sunitinib was administered for 4 weeks of a 6-week cycle for the first cycle. We evaluated the association of sunitinib-induced toxicities and clinical outcomes with the trough total sunitinib concentration in a steady state during the first cycle. ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "Results:\nThe median total sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL). There was an association between total sunitinib concentration and the severity of thrombocytopenia, anorexia, and fatigue. Patients with ≥ 100 ng/mL total sunitinib (n = 8), compared with patients with \u003c 100 ng/mL (n = 13), had a greater incidence of Grade ≥ 3 toxicities (6 patients [75.0%] vs. 3 patients [23.1%]). Patients with \u003c 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02). ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "Conclusion:\nResults of this study suggest that therapeutic drug monitoring of sunitinib could be useful for avoiding severe toxicities. Dose reduction might be needed, especially when the total sunitinib concentration is ≥ 100 ng/mL, to avoid unnecessary early discontinuation of treatment. ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_6_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Thesis or Dissertation", "subitem_description_type": "Other"}]}, "item_6_description_69": {"attribute_name": "学位授与年度", "attribute_value_mlt": [{"subitem_description": "平成27年度", "subitem_description_language": "ja", "subitem_description_type": "Other"}]}, "item_6_dissertation_number_71": {"attribute_name": "学位授与番号", "attribute_value_mlt": [{"subitem_dissertationnumber": "甲第736号"}]}, "item_6_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier", "subitem_publisher_language": "en"}]}, "item_6_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "25701374", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1016/j.clgc.2015.01.007"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1016/j.clgc.2015.01.007", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2015 Elsevier Inc. All rights reserved. "}]}, "item_6_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1558-7673", "subitem_source_identifier_type": "PISSN"}]}, "item_6_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "NODA, Satoshi", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-02-17"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Noda-sunitinib-CGC-2015.pdf", "filesize": [{"value": "471.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 471600.0, "url": {"label": "Noda-sunitinib-CGC-2015.pdf", "objectType": "fulltext", "url": "https://shiga-med.repo.nii.ac.jp/record/2917/files/Noda-sunitinib-CGC-2015.pdf"}, "version_id": "7b54215f-6359-4da6-bebb-d9e7986f209e"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Individualized pharmacotherpy", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Kidney cancer", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pharmacokinetics", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Tolerability", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Tyrosine kinase inhibitor", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "doctoral thesis", "resourceuri": "http://purl.org/coar/resource_type/c_db06"}]}, "item_title": "Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "11", "path": ["37"], "permalink_uri": "http://hdl.handle.net/10422/11691", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2016-05-17"}, "publish_date": "2016-05-17", "publish_status": "0", "recid": "2917", "relation": {}, "relation_version_is_last": true, "title": ["Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma."], "weko_shared_id": -1}
Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
http://hdl.handle.net/10422/11691
http://hdl.handle.net/10422/11691a5ca0e8d-452c-4343-8ec4-0e9aed329d80
名前 / ファイル | ライセンス | アクション |
---|---|---|
Noda-sunitinib-CGC-2015.pdf (471.6 kB)
|
|
Item type | 学位論文 / Thesis or Dissertation(1) | |||||||
---|---|---|---|---|---|---|---|---|
公開日 | 2016-05-17 | |||||||
タイトル | ||||||||
言語 | en | |||||||
タイトル | Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. | |||||||
言語 | ||||||||
言語 | eng | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | Individualized pharmacotherpy | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | Kidney cancer | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | Pharmacokinetics | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | Tolerability | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | Tyrosine kinase inhibitor | |||||||
資源タイプ | ||||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||
資源タイプ | doctoral thesis | |||||||
アクセス権 | ||||||||
アクセス権 | open access | |||||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||
著者 |
NODA, Satoshi
× NODA, Satoshi
|
|||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Background: Sunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). Sunitinib pharmacokinetics shows a large interpatient variability. |
|||||||
言語 | en | |||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Patients and methods: A retrospective, observational clinical study of 21 patients with RCC was performed. Sunitinib was administered for 4 weeks of a 6-week cycle for the first cycle. We evaluated the association of sunitinib-induced toxicities and clinical outcomes with the trough total sunitinib concentration in a steady state during the first cycle. |
|||||||
言語 | en | |||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Results: The median total sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL). There was an association between total sunitinib concentration and the severity of thrombocytopenia, anorexia, and fatigue. Patients with ≥ 100 ng/mL total sunitinib (n = 8), compared with patients with < 100 ng/mL (n = 13), had a greater incidence of Grade ≥ 3 toxicities (6 patients [75.0%] vs. 3 patients [23.1%]). Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02). |
|||||||
言語 | en | |||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Conclusion: Results of this study suggest that therapeutic drug monitoring of sunitinib could be useful for avoiding severe toxicities. Dose reduction might be needed, especially when the total sunitinib concentration is ≥ 100 ng/mL, to avoid unnecessary early discontinuation of treatment. |
|||||||
言語 | en | |||||||
学位名 | ||||||||
言語 | ja | |||||||
学位名 | 博士(医学) | |||||||
学位授与機関 | ||||||||
学位授与機関識別子Scheme | kakenhi | |||||||
学位授与機関識別子 | 14202 | |||||||
言語 | ja | |||||||
学位授与機関名 | 滋賀医科大学 | |||||||
学位授与年度 | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | 平成27年度 | |||||||
言語 | ja | |||||||
学位授与年月日 | ||||||||
学位授与年月日 | 2015-09-09 | |||||||
学位授与番号 | ||||||||
学位授与番号 | 甲第736号 | |||||||
書誌情報 |
en : Clinical Genitourinary Cancer 巻 13, 号 4, p. 350-358, 発行日 2015-08 |
|||||||
出版者 | ||||||||
言語 | en | |||||||
出版者 | Elsevier | |||||||
権利 | ||||||||
権利情報 | © 2015 Elsevier Inc. All rights reserved. | |||||||
著者版フラグ | ||||||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
ISSN | ||||||||
収録物識別子タイプ | PISSN | |||||||
収録物識別子 | 1558-7673 | |||||||
PMID | ||||||||
識別子タイプ | PMID | |||||||
関連識別子 | 25701374 | |||||||
DOI | ||||||||
識別子タイプ | DOI | |||||||
関連識別子 | https://doi.org/10.1016/j.clgc.2015.01.007 | |||||||
関連名称 | 10.1016/j.clgc.2015.01.007 | |||||||
資源タイプ | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | Thesis or Dissertation |